Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG940

—

39e87dc6-9f15-58a3-8160-614bdd80eec4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.303
  • TGF_BETA_SIGNALING+0.265
  • MITOTIC_SPINDLE+0.253
  • ESTROGEN_RESPONSE_EARLY+0.175
  • HEME_METABOLISM+0.161
  • NOTCH_SIGNALING+0.157
  • ESTROGEN_RESPONSE_LATE+0.155
  • BILE_ACID_METABOLISM+0.140
  • APICAL_SURFACE+0.137
  • G2M_CHECKPOINT+0.137

Top 10 suppressed

  • MYC_TARGETS_V2-0.419
  • ALLOGRAFT_REJECTION-0.368
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.329
  • TNFA_SIGNALING_VIA_NFKB-0.310
  • INFLAMMATORY_RESPONSE-0.305
  • UNFOLDED_PROTEIN_RESPONSE-0.303
  • MYC_TARGETS_V1-0.302
  • PANCREAS_BETA_CELLS-0.282
  • OXIDATIVE_PHOSPHORYLATION-0.277
  • MTORC1_SIGNALING-0.242

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG1049
mng-umap@100
——0.747
2MNG920
mng-umap@100
——0.738
3MNG420
mng-umap@100
——0.738
4MNG13
mng-umap@100
——0.736
5MNG522
mng-umap@100
——0.731
6MNG699
mng-umap@100
——0.731
720050020.LumB
breast-umap@18
—B0.719
8C3N-00199
lung-landscapes@6
—cohortA10.717
9MNG1173
mng-umap@100
——0.705
10MNG660
mng-umap@100
——0.703

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.303Remibrutinib— uncovered
TGF_BETA_SIGNALING0.265Inavolisib— uncovered
MITOTIC_SPINDLE0.253Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.175Inavolisib— uncovered
HEME_METABOLISM0.161Temsirolimus— uncovered
NOTCH_SIGNALING0.157Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.155Idelalisib— uncovered
BILE_ACID_METABOLISM0.140Inavolisib— uncovered
APICAL_SURFACE0.137Temsirolimus— uncovered
G2M_CHECKPOINT0.137Inavolisib— uncovered
SPERMATOGENESIS0.084Inavolisib— uncovered
UV_RESPONSE_DN0.080Inavolisib— uncovered
PEROXISOME0.079Idelalisib— uncovered
E2F_TARGETS0.077Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.075Inavolisib— uncovered
APICAL_JUNCTION0.073Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.065Inavolisib— uncovered
ANDROGEN_RESPONSE0.061Inavolisib— uncovered
ADIPOGENESIS0.027Inavolisib— uncovered
FATTY_ACID_METABOLISM0.022Inavolisib— uncovered